Jci_page_head_homepage_01 Jci_page_head_homepage_02
Helen M. Marriott, Colin D. Bingle, Robert C. Read, Karen E. Braley, Guido Kroemer, Paul G. Hellewell, Ruth W. Craig, Moira K.B. Whyte, David H. Dockrell
Published in Volume 115, Issue 2
J Clin Invest. 2005; 115(2):359–368 doi:10.1172/JCI21766
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 5

Proteasome-mediated degradation of Mcl-1 is associated with pneumococcal-associated macrophage apoptosis. (A) Western blot of total protein obtained from MDMs 12 hours and 20 hours after mock infection or infection with pneumococci in the presence or absence of the proteasome inhibitor MG-132, probed with anti–Mcl-1 and anti-actin antibodies. Data are representative of 4 donors in 2 independent experiments. (B) Western blot of the cytosolic fractions from MDMs 20 hours after infection in the presence or absence of MG-132 probed with anti–cytochrome c and anti-actin antibodies. Results are representative of 3 donors from 2 independent experiments. (C) MDMs were incubated in the presence or absence of MG-132, and nuclear features of apoptosis were recorded 20 hours after infection. Results were obtained from 6 donors tested in duplicate. Dunn’s multiple comparison test: MDMs infected with pneumococci without MG-132 vs. with MG-132, P < 0.05. Data are representative of 3 experiments.